FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.845 USD
0.021 (2.49%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2025-03-18
0
-20.76
-0.98
2018.37%
2024-11-14
0
-18.27
-7.38
147.56%
2024-08-13
0
-0.99
0
-
2024-05-15
0
0
0
-
